Literature DB >> 17939684

The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.

Hiroshi Yamaguchi1, Stewart R Durell, Deb K Chatterjee, Carl W Anderson, Ettore Appella.   

Abstract

The wild-type p53-induced phosphatase Wip1 (PP2Cdelta or PPM1D) is a member of the protein phosphatase 2C (PP2C) family and controls cell cycle checkpoints in response to DNA damage. p38 MAPK and ATM were identified as physiological substrates of Wip1, and we previously reported a substrate motif that was defined using variants of the p38(180pT 182pY) diphosphorylated peptide, TDDEMpTGpYVAT. However, the substrate recognition motifs for Wip1 have not been fully defined as the sequences surrounding the targeted residues in ATM and p38 MAPK appear to be unrelated. Using a recombinant human Wip1 catalytic domain (rWip1), in this study we measured the kinetic parameters for variants of the ATM(1981pS) phosphopeptide, AFEEGpSQSTTI. We found that rWip1 dephosphorylates phosphoserine and phosphothreonine in the p(S/T)Q motif, which is an essential requirement for substrate recognition. In addition, acidic, hydrophobic, or aromatic amino acids surrounding the p(S/T)Q sequence have a positive influence, while basic amino acids have a negative influence on substrate dephosphorylation. The kinetic constants allow discrimination between true substrates and nonsubstrates of Wip1, and we identified several new putative substrates that include HDM2, SMC1A, ATR, and Wip1 itself. A three-dimensional molecular model of Wip1 with a bound substrate peptide and site-directed mutagenesis analyses suggested that the important residues for ATM(1981pS) substrate recognition are similar but not identical to those for the p38(180pT 182pY) substrate. Results from this study should be useful for predicting new physiological substrates that may be regulated by Wip1 and for developing selective anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17939684     DOI: 10.1021/bi701096s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

Review 1.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

2.  A small molecular scaffold for selective inhibition of Wip1 phosphatase.

Authors:  Jeong Bang; Hiroshi Yamaguchi; Stewart R Durell; Ettore Appella; Daniel H Appella
Journal:  ChemMedChem       Date:  2008-02       Impact factor: 3.466

3.  LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro.

Authors:  J Jacob Wamsley; Natalia Issaeva; Hanbing An; Xinyuan Lu; Lawrence A Donehower; Wendell G Yarbrough
Journal:  Cell Cycle       Date:  2016-12-27       Impact factor: 4.534

4.  ATM/Wip1 activities at chromatin control Plk1 re-activation to determine G2 checkpoint duration.

Authors:  Himjyot Jaiswal; Jan Benada; Erik Müllers; Karen Akopyan; Kamila Burdova; Tobias Koolmeister; Thomas Helleday; René H Medema; Libor Macurek; Arne Lindqvist
Journal:  EMBO J       Date:  2017-06-12       Impact factor: 11.598

Review 5.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

6.  Wild-type p53-induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand break repair.

Authors:  Sung-Hwan Moon; Lin Lin; Xinna Zhang; Thuy-Ai Nguyen; Yolanda Darlington; Alan S Waldman; Xiongbin Lu; Lawrence A Donehower
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

7.  Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.

Authors:  Aidan G Gilmartin; Thomas H Faitg; Mark Richter; Arthur Groy; Mark A Seefeld; Michael G Darcy; Xin Peng; Kelly Federowicz; Jingsong Yang; Shu-Yun Zhang; Elisabeth Minthorn; Jon-Paul Jaworski; Michael Schaber; Stan Martens; Dean E McNulty; Robert H Sinnamon; Hong Zhang; Robert B Kirkpatrick; Neysa Nevins; Guanglei Cui; Beth Pietrak; Elsie Diaz; Amber Jones; Martin Brandt; Benjamin Schwartz; Dirk A Heerding; Rakesh Kumar
Journal:  Nat Chem Biol       Date:  2014-01-05       Impact factor: 15.040

8.  Deficiency of the tumor promoter gene wip1 induces insulin resistance.

Authors:  Heather L Armata; Sally Chamberland; Lauren Watts; Hwi Jin Ko; Yongjin Lee; Dae Young Jung; Jason K Kim; Hayla K Sluss
Journal:  Mol Endocrinol       Date:  2015-01

9.  Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression.

Authors:  Arne Lindqvist; Menno de Bruijn; Libor Macurek; Alexandra Brás; Anneloes Mensinga; Wytse Bruinsma; Olaf Voets; Onno Kranenburg; René H Medema
Journal:  EMBO J       Date:  2009-08-27       Impact factor: 11.598

10.  PPM1A is a RelA phosphatase with tumor suppressor-like activity.

Authors:  X Lu; H An; R Jin; M Zou; Y Guo; P-F Su; D Liu; Y Shyr; W G Yarbrough
Journal:  Oncogene       Date:  2013-07-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.